Dementia - STAT

First Opinion By Madhav Thambisetty

Why a controversial decision won’t stop me from serving on FDA advisory committees

First Opinion Podcast By Patrick Skerrett

Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm

First Opinion By Sam Gandy

6 ways the FDA’s approval of Aduhelm does more harm than good

Health By Elizabeth Cooney

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Pharmalot By Ed Silverman

‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine

Biotech By Nicholas Florko

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug

Biotech By Damian Garde

Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug

Speaker Pelosi Introduces Flagship Prescription Drug Costs Bill

Politics By Nicholas Florko

Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

Health By Andrew Joseph

Elation, pride, and a slew of questions: Clinical trial participants reflect on their own complicated reactions to Aduhelm approval

Biotech By Damian Garde

Biogen’s big day is a Wall Street windfall for biotechs in Alzheimer’s

Health By Andrew Joseph

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

First Opinion By Dana Goldman and Darius Lakdawalla

FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs

Health By Usha Lee McFarling

A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care

dementia alzheimer's disease progression

First Opinion By Nora Super and Diane Ty

Routine cognitive screening can help detect early signs of dementia

Pharmalot By Ed Silverman

Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500

Exclusive By Megan Molteni

Six patients with dementia went to Mexico for an unproven gene therapy, a biotech CEO claims

First Opinion By Patrick Skerrett

A caregiver and physician discuss the financial implications of dementia

First Opinion By Jason Karlawish

The long, exhausting reach of dementia care

The Readout LOUD By Damian Garde and Adam Feuerstein

Listen: Europe’s vaccine safety scare, Lilly’s Alzheimer’s data, & a plea for transparency

In the Lab By Usha Lee McFarling

New monkey model of Alzheimer’s disease may accelerate search for human treatments

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy

Biotech By Damian Garde

Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value

Health By Alissa Ambrose

Most Read

FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline

Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

FAQs: What you need to know about the Alzheimer’s drug Aduhelm

Why Biogen may be sitting on the most lucrative product in pharmaceutical history

By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk

Biogen, FDA at odds over timing of crucial confirmatory trial of Alzheimer’s drug

Bad medicine: aducanumab is a lackluster drug with a high price tag

All Coverage

Why a controversial decision won’t stop me from serving on FDA advisory committees

Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm

6 ways the FDA’s approval of Aduhelm does more harm than good

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug

Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug

Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

Elation, pride, and a slew of questions: Clinical trial participants reflect on their own complicated reactions to Aduhelm approval

Biogen’s big day is a Wall Street windfall for biotechs in Alzheimer’s

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs

A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care

Routine cognitive screening can help detect early signs of dementia

Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500

Six patients with dementia went to Mexico for an unproven gene therapy, a biotech CEO claims

A caregiver and physician discuss the financial implications of dementia

The long, exhausting reach of dementia care

Listen: Europe’s vaccine safety scare, Lilly’s Alzheimer’s data, & a plea for transparency

New monkey model of Alzheimer’s disease may accelerate search for human treatments

Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring

Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy

Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value

Picturing the ‘patience, love, and devotion’ of Alzheimer’s care